CASI Pharmaceuticals Closes Final US$5 Million Tranche of US$20 Million Convertible Notes

CASI Pharmaceuticals ( (CASIF) ) has issued an announcement.

CASI Pharmaceuticals said on April 20, 2026 that it has closed the fourth and final US$5 million tranche of its previously announced US$20 million convertible note financing with ETP Global III Fund LP, an entity controlled by chairman Wei-Wu He. The 36‑month note carries a 12% annual interest rate and can be converted into CASI ordinary shares at a volume-weighted average price capped at US$2 and floored at US$1, bolstering the company’s funding flexibility while introducing potential future equity dilution for shareholders.

The most recent analyst rating on (CASIF) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASIF Stock Forecast page.

Spark’s Take on CASIF Stock

According to Spark, TipRanks’ AI Analyst, CASIF is a Neutral.

The score is primarily weighed down by poor financial performance (declining revenue, ongoing losses, negative and worsening free cash flow, and very high leverage). Technicals are somewhat improved in the short term but remain weak versus longer-term trend levels, while valuation is difficult to support due to negative earnings and no dividend yield data.

To see Spark’s full report on CASIF stock, click here.

More about CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a Beijing-headquartered, clinical-stage biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody. The company is targeting indications in organ transplant rejection and autoimmune diseases, positioning itself in specialized immunology and transplant-related markets.

Average Trading Volume: 209,386

Technical Sentiment Signal: Sell

Current Market Cap: $2.32M

See more insights into CASIF stock on TipRanks’ Stock Analysis page.